AIRS Medical Raises $6.24M for AI Imaging Global Expansion

Seoul-based AIRS Medical, a pioneer in artificial intelligence for medical imaging, has successfully secured a significant follow-on investment totaling $6.24 million. This latest capital infusion was led by Dunamu & Partners, the venture capital arm of digital platform giant Dunamu, which previously supported AIRS Medical during its Series C funding round in 2024. The round also saw participation from global private equity firm TA Associates, underscoring strong investor confidence in the company's innovative technology and market potential.

The newly acquired funds are earmarked for aggressive global expansion, with a strategic focus on penetrating key markets in the United States and Europe. AIRS Medical also intends to broaden the clinical applications of its existing solutions and invest in the development of next-generation AI technologies. This strategic push aims to solidify the company's position as a leader in the rapidly evolving field of AI-driven medical diagnostics.

AIRS Medical is renowned for its proprietary AI solutions, including SwiftMR, which dramatically reduces MRI scan durations by up to 50% while simultaneously enhancing image quality. Complementing this is SwiftSight, a platform designed for advanced MRI quantification and structured reporting. These technologies are already making a substantial impact, being utilized in over 1,700 medical institutions across more than 40 countries and supporting in excess of 6 million AI-assisted scans annually. The efficiency gains and diagnostic improvements offered by AIRS Medical are particularly relevant in today's healthcare environment, where optimizing throughput and diagnostic accuracy are paramount.

The broader market for AI in healthcare is experiencing exponential growth, projected to reach tens of billions of dollars in the coming years. Companies like AIRS Medical are at the forefront of this transformation, addressing critical needs such as reducing patient wait times and improving the precision of diagnostic imaging. The ability to accelerate scan times without compromising image fidelity is a significant value proposition, especially for complex procedures like MRIs, which can be time-consuming and costly.

Jangsoon Park, CEO of AIRS Medical, expressed his commitment to leveraging this new funding to further the company's mission. "Our focus will be on expanding our business in core markets like the US and Europe and developing next-generation AI technology to solidify our leadership in the global medical imaging AI category," Park stated. This forward-looking strategy highlights the company's ambition to not only grow its market share but also to drive innovation in AI-powered medical imaging.

The investment from Dunamu & Partners and TA Associates signifies a strong endorsement of AIRS Medical's technological prowess and its potential to disrupt the medical imaging sector. As healthcare systems worldwide increasingly adopt digital solutions, AIRS Medical is well-positioned to capitalize on this trend, offering tangible benefits in terms of efficiency, cost-effectiveness, and diagnostic outcomes.